Gene expression profiles in esophageal adenocarcinoma predict survival after resection

Pennathur, Arjun; Xi, Liqiang; Litle, Virginia R.; Gooding, William E.; Krasinskas, Alyssa M.; Landreneau, Rodney J.; Godfrey, Tony E.; Luketich, James D.

doi:10.1016/j.jtcvs.2012.10.031

Cited by 24 publications

(22 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SPARC expression itself was shown to correlate with poor survival in esophageal cancer [14]. Based on both published marker genes that are predictive for survival [8] and on a Kaplan-Meier survival analysis we showed that high IMP2 expression was linked to short survival. The prognostic relevance of IMP2 expression has been described for other cancer types [15–17].…”

Section: Discussionmentioning

confidence: 91%

“…Although, IMP2 expression was not related to lymph node metastasis (data not shown), distant metastasis showed increased IMP2 protein levels compared to primary tumor tissue (Figure 3C; Table 1; p = 0.0042). In order to test whether IMP2 expression correlates with prognosis, we analyzed the marker genes shown to be predictive for survival defined by Pennathur et al [8] in the gene expression dataset GSE13898. Pennathur's marker genes had similar expression profiles in this dataset suggesting similar survival relations for the clustered samples.…”

Section: Resultsmentioning

confidence: 99%

“…Scale bars: 50 μm. ( D ) Heatmap showing expression of IMP2 (bottom row) and 52 marker genes for poor prognosis described by Pennathur et al [8] in esophageal adenocarcinoma ( n = 64; GSE13898). ( E ) Kaplan-Meier survival plot referring to low and high IMP2 expression levels in TCGA dataset ( n = 57).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Elevated expression of the IGF2 mRNA binding protein 2 (IGF2BP2/IMP2) is linked to short survival and metastasis in esophageal adenocarcinoma

et al. 2016

View full text Add to dashboard Cite

Esophageal adenocarcinoma (EAC) represents the sixth leading cause of cancer-related deaths and develops in Barret's esophagus affected tissues. The IGF2 mRNA binding protein IMP2/IGF2BP2/p62 was originally identified as an autoantigen in hepatocellular carcinoma. Aim of this study was to investigate the expression and prognostic role of IMP2 in EAC. Human EAC and Barret's esophagus tissue showed overexpression of IMP2, particularly in tumors of increased size and in metastatic tissues. Molecular classification based on published gene signatures of esophageal cancer revealed a specific subtype, in which the expression of IMP2 is high. According to GO and KEGG pathway analyses, genes showing highly correlated expression with IMP2 are associated with growth, proliferation, metabolism, inflammation, and cancerous processes. Clustering of EAC samples according to published survival marker genes strongly suggests that IMP2 overexpressing samples show poor survival. Finally, IMP2 expression correlated with short survival in patients with EAC or esophageal squamous carcinoma. Our data indicate that IMP2 might be a useful prognostic marker for Barret's esophagus and EAC.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Elevated expression of the IGF2 mRNA binding protein 2 (IGF2BP2/IMP2) is linked to short survival and metastasis in esophageal adenocarcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Gene expression profiles have been identified that can be used to prospectively place patients in high-risk and low-risk survival cohorts following esophagectomy according to their tumor's genetic signature (15) and to accurately predicted prognosis and chemosensitivity, and chemoresistance to various adjuvant chemotherapeutic agents (16). Finally, microarray analyses have also led to the identification of novel oncogenic genes that may one day serve as potential therapeutic targets in the future (12).…”

Section: Molecular Medicinementioning

confidence: 99%

Future directions in esophageal cancer therapy

Wald

Smaglo

Mok

et al. 2017

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

Resection techniques for esophageal carcinoma continue to evolve, from endoscopic mucosal resection or endoscopic submucosal dissection for early stage disease to standard and robot-assisted minimally invasive esophagectomy as part of multimodal therapy for locally advanced disease. Though currently limited to assessing conduit perfusion and sentinel lymph nodes, embedded technology in the robotic surgical platform will likely play an expanded role during esophagectomy in the future. The use of targeted therapies, checkpoint inhibitors, engineered immune cell therapy, and cancer vaccines show promise in the treatment of systemic disease. Radiation therapy techniques are becoming increasingly sophisticated and they may play a more active role in stage IV disease in the future.

show abstract

“…Notable modifications to previous staging classifications made in this most recent edition include the classification of T4 lesions as resectable (T4a) or unresectable (T4b), the stratification of N stage by number of nodes involved, and the stratification of stage according to tumor histology, degree of differentiation (grade), and location (1,(7)(8)(9) (Table 1). In the future, refinements in molecular staging of esophageal cancer with analysis of gene expression profiles may also play a role in risk stratification and in the treatment algorithm of esophageal cancer (10).…”

Section: Esophageal Cancer Stagingmentioning

confidence: 99%

Minimally invasive staging of esophageal cancer

Mehta¹,

Bianco²,

Awais³

et al. 2017

ASVIDE

Self Cite

View full text Add to dashboard Cite

Esophageal cancer is one of the most common malignancies in the world today and the sixth-leading cause of cancer-related mortality. Accurate preoperative staging of esophageal cancer is imperative to the selection of appropriate treatments. Patients with esophageal carcinomas typically undergo a multimodality staging process including noninvasive imaging techniques, such as computed tomography (CT) and positron emission tomography (PET), as well as endoscopic ultrasound (EUS), which is slightly more invasive.Minimally invasive surgical staging, with laparoscopy, occasionally in combination with video-assisted thoracoscopy, is used in the staging process at select institutions and has been shown to be more accurate than noninvasive staging modalities. Two major advantages of minimally invasive surgical staging over conventional techniques are the improved assessment of locoregional disease and enhanced identification of distant metastases. These advantages decrease the likelihood that the patient will undergo a nontherapeutic laparotomy. Currently, no clear consensus exists regarding which patients with esophageal cancer would benefit most from the addition of minimally invasive surgical staging. We have, however, found that minimally invasive surgical staging with laparoscopy is particularly valuable in detection of occult distant metastases. In this article, we summarize the staging modalities for esophageal cancer including minimally invasive surgical staging.

show abstract

Gene expression profiles in esophageal adenocarcinoma predict survival after resection

Cited by 24 publications

References 37 publications

Elevated expression of the IGF2 mRNA binding protein 2 (IGF2BP2/IMP2) is linked to short survival and metastasis in esophageal adenocarcinoma

Elevated expression of the IGF2 mRNA binding protein 2 (IGF2BP2/IMP2) is linked to short survival and metastasis in esophageal adenocarcinoma

Future directions in esophageal cancer therapy

Minimally invasive staging of esophageal cancer

Contact Info

Product

Resources

About